PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Olanzapine Matches Dexmedetomidine for Delirium, Signals Lower Mortality

olanzapinedexmedetomidineantipsychoticsalpha-2 agonistsICU deliriumsedationcritical carerandomized controlled trialmortalityCAM-ICU Critical Care / ICU

Background Information

Olanzapine and dexmedetomidine offer dual options for ICU delirium management.

Managing delirium in critically ill patients can significantly affect outcomes, including length of ICU stay and overall recovery. The study found olanzapine and low-dose dexmedetomidine both effective for delirium, but with different side effect profiles. This study informs clinicians on alternative pharmacological strategies for ICU delirium, noting the potential side effects and efficacy of each option. Olanzapine and dexmedetomidine are effective for ICU delirium with varying side effect considerations.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Liu J, Wang C, Nie X, Yang R, Wang M, Ma X, Xu K, Wu G, Li D, Liu S

Citation: Liu J, Wang C, Nie X, et al. Olanzapine versus low-dose dexmedetomidine for delirium in patients with critical illness: a randomized clinical trial. American journal of respiratory and critical care medicine. 2026;212(8):1845-1848. doi:10.1093/ajrccm/aamag235

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.